Novo Nordisk's late stage diabetes candidate semaglutide has scored another victory, outperforming Eli Lilly’s Trulicity in controlling glucose levels and body weight. The phase 3 trial success ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback